Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GST101
- Development stage
- Phase 2
- Lead developer
- Seed Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GST101 is an oral small molecule inhibitor targeting the RAS pathway, developed by Genuine Seed Therapeutics for the treatment of RAS-mutant advanced solid tumors. It is designed to block oncogenic signaling driven by RAS mutations or amplifications. GST101 is currently being evaluated in a Phase I/II clinical trial as a monotherapy for adult patients with advanced solid tumors, with specific cohorts exploring its efficacy in RAS-mutant non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic ductal adenocarcinoma.
02
Targets
HRAS (H-Ras protein)
Beyond the preview
Go deeper on GST101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GST101.